Application of cresol in drugs for treating coronavirus infectious diseases

The problem that existing antiviral drugs cannot effectively prevent or treat infectious diseases of coronavirus, especially diseases caused by human coronavirus HCoV-229E, is solved by using drug preparations prepared by cresol, providing a problem of infectious diseases of this virus. Effective treatment and prevention options and provide clinical medication options for patients without autonomous inhalation, significantly reducing the lung index of pneumonia.

CN114073685BActive Publication Date: 2024-12-06INCREASEPHARM HENGQIN INST CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202010834221.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-08-18
Publication Date
2024-12-06
Estimated Expiration
2040-08-18

AI Technical Summary

Technical Problem

Existing antiviral drugs cannot effectively prevent or treat infectious coronavirus diseases, especially diseases caused by human coronavirus HCoV-229E, and lack clinical drug options for infants and young children who do not have the ability to inhale or patients with active dyspnea.

Method used

Using cresol as the active ingredient, a pharmaceutical preparation for the prevention or treatment of infectious diseases of coronavirus, including liquid or solid preparations of cresol and appropriate drug excipients, specifically atomized inhalation preparations, by dilution, stirring and Prepared after micropore filtration, suitable for patients without autonomous inhalation.

Benefits of technology

In the trial of human coronavirus HCoV-229E-infected mice, cresol significantly reduced the lung index and showed good therapeutic effects. It has a significant inhibitory effect on pneumonia caused by HCoV-229E, providing a coronavirus-infected disease Effective prevention and treatment plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002637545050000011
    Figure BDA0002637545050000011
  • Figure BDA0002637545050000041
    Figure BDA0002637545050000041
  • Figure BDA0002637545050000051
    Figure BDA0002637545050000051
Patent Text Reader

Abstract

The present invention belongs to the field of drug therapy, and specifically relates to the use of cresol in the preparation of drugs for treating viral infectious diseases. The present invention discloses the use of cresol and its inhalation preparation in the treatment of coronavirus infectious diseases. The new use of cresol inhalation solution was verified in a mouse test infected with human coronavirus HCoV-229E. The technical solution has novelty, and the efficacy test of cresol inhalation solution in the treatment of pneumonia caused by HCoV-229E virus infection was carried out. The results showed that the cresol inhalation solution showed good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, and could significantly reduce the mouse lung index.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of drug therapy, and in particular to application of cresol in preparing drugs for treating viral infectious diseases. Background Art

[0002] Cresol, also known as Lysol, is a mixture of o-cresol (Formula I), m-cresol (Formula II) and p-cresol (Formula III), with CAS number 1319-77-3, molecular formula C7H8O, and molecular weight 108.14.

[0003]

[0004] Cresol is a common disinfectant preservative. Cresol has low solubility in water, and is often mixed with water in the form of cresol soap solution (Lysol). Cresol soap solution is a soap solution whose main component is cresol, and the main bactericidal component is cresol. The concentration and action time of cresol are as follows: 1% to 5% aqueous solution is sprayed or wiped on the surface of contaminated objects, and the action time is 30 to 60 minutes; 5% aqueous solution is used to kill crystalline nucleobacterium, and the action time is 1 to 2 hours; 1 to 2% aqueous solution is used for hand and skin disinfection; 3% to 5% aqueous solution is used for instrument and appliance disinfection; 5 to 10% aqueous solution is used for excrement disinfection; 0.15% to 0.3% can be used as an antibacterial preservative for subcutaneous and intradermal injection dosage forms. At appropriate concentrations, cresol has a killing effect on most reproductive bacteria and fungi that do not produce spores. A solution containing 0.3%-0.6% cresol can kill most pathogenic bacteria in 10 minutes, but it has a weak effect on spores. Killing spores requires a higher concentration and a longer time. Cresol has antibacterial activity that is not easily affected by organic matter and the number of bacteria in the environment, has stable chemical properties, and its efficacy will not change during storage or exposure to heat, and its effective concentration can be maintained for a long time.

[0005] Coronavirus belongs to the Coronaviridae family. It is an enveloped, non-segmented, positive-stranded single-stranded RNA virus with a virus particle diameter of 80 to 120 nm. Its structure from the outside to the inside is: spikes, outer membrane, envelope, capsid, and genome. There are spikes on the envelope, which appear crown-shaped under an electron microscope, hence the name. The coronavirus genome is 26 to 32 kb long, with two overlapping open reading frames ORF1a and ORF1b at the 5' end, encoding two replicase polyprotein precursors pp1a and pp1ab. The polyprotein pp1ab contains a protease that can cleave the polyprotein precursor into a series of non-structural proteins (nps) necessary for the generation of new virus particles; the remaining reading frames encode viral structural proteins, including spike glycoprotein (S), membrane protein (M), envelope protein (E), nucleocapsid protein (N) and virus replication auxiliary proteins. Coronaviruses are widely present in nature. They were first isolated from poultry in 1937 and first found in humans in 1965. Coronaviruses are divided into four genera (α, β, γ, δ). Seven coronaviruses that can infect humans have been identified, of which four (HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1) are relatively common in the population and have low pathogenicity, generally causing mild respiratory diseases similar to the common cold; the other three (SARS-CoV, SARS-CoV-2, and MERS-CoV) are highly pathogenic and contagious. In the past 20 years, new variants of coronaviruses have continued to emerge, and while their pathogenicity has increased, they have also shown the characteristics of spreading from local outbreaks to the world, posing a great threat to global health.

[0006] Existing antiviral drugs cannot meet the needs of human health, so there is an urgent need for the emergence of an antiviral drug. Summary of the invention

[0007] In response to the above clinical needs, we have screened a large number of phenolic compounds for efficacy, and the present invention provides the use of cresol in the preparation of drugs for treating or preventing coronavirus infection diseases. At present, there is no report on the above application, especially the use of cresol in the treatment of human coronavirus HCoV-229E infection diseases. In addition, the present invention also provides a cresol inhalation preparation, which provides more clinical drug options for infants, children or patients with active breathing difficulties who are unable to inhale autonomously.

[0008] The object of the present invention is to provide an application of cresol in preparing a medicine for preventing or treating coronavirus infectious diseases.

[0009] The molecular formula of the cresol is C7H8O, the molecular weight is 108.14, and it is a mixture of o-cresol, m-cresol and p-cresol.

[0010] Preferably, the coronavirus infectious disease is a disease caused by infection with human coronavirus HCoV-229E.

[0011] Preferably, the diseases caused by infection with human coronavirus HCoV-229E include pneumonia, nephritis and hepatitis.

[0012] Preferably, the drug for preventing or treating coronavirus infectious diseases refers to a pharmaceutical preparation containing cresol.

[0013] in,

[0014] The pharmaceutical preparation is a liquid preparation or a solid preparation prepared from cresol and appropriate pharmaceutical excipients.

[0015] The preparation may be an inhalation preparation, an injection, an oral preparation or a nasal spray.

[0016] More preferably, in the inhalation preparation, the mass percentage of cresol is 0.03%-0.6%, and further preferably 0.07%-0.3%.

[0017] Among them, the inhalation preparation refers to an atomized inhalation solution, and the prescription composition is cresol, sodium chloride and water for injection.

[0018] Preferably, the amount of cresol used is 0.03g-0.6g, the amount of sodium chloride used is 8.0g-10.0g, and the amount of water for injection is added to a solution volume of 1000ml.

[0019] The specific preparation method is:

[0020] Weigh the prescribed amount of cresol and sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute and stir evenly, filter through a microporous filter membrane, and prepare according to the aseptic production process to obtain the product.

[0021] Beneficial effects of the present invention: The technical solution of the present invention verifies the new use of cresol in a mouse test infected with human coronavirus HCoV-229E, and the technical solution has novelty, and conducts a test on the efficacy of cresol in treating pneumonia caused by HCoV-229E virus infection. The test results show that cresol exhibits good efficacy in the lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus. The present invention also shows the application examples of cresol as an antiviral drug through examples. DETAILED DESCRIPTION

[0022] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be described in further detail below.

[0023] Test Example 1

[0024] The pneumonia model of mice infected with human coronavirus HCoV-229E was used to evaluate the therapeutic effects of different phenolic compounds on the pneumonia model of mice infected with human coronavirus HCoV-229E from two aspects: lung index and inhibition rate.

[0025] 1. Experimental Materials

[0026] 1.1 The cell line was mouse mononuclear macrophage RAW264.7, purchased from Beijing Beina Chuanglian Biotechnology Research Institute, passaged in our laboratory, and stored in liquid nitrogen for future use.

[0027] 1.2 The virus strain is human coronavirus HCoV-229E, provided by the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, propagated in this laboratory, and stored in a -80°C refrigerator for future use.

[0028] 1.3 The concentration of the tested drugs was 0.2% for phloroglucinol, 0.2% for amylmetacresol, and 0.2% for cresol.

[0029] 1.4 Experimental reagents are shown in Table 1.

[0030] Table 1:

[0031] Reagent name batch number Manufacturer Reagent use Ether 20150417 Sinopharm Chemical Reagent Co., Ltd. Mouse anesthesia

[0032] 1.5 Experimental instruments are shown in Table 2.

[0033] Table 2:

[0034]

[0035] 2. Experimental Methods

[0036] 2.1 Drug preparation

[0037] Preparation of the test drug: refer to Examples 1-3, and inhale by nebulization according to the above concentrations, 10 minutes each time, once a day, for 4 consecutive days.

[0038] 2.2 Virus Passaging

[0039] Take a 25cm tube of RAW264.7 cells grown into a monolayer 2The culture flask was discarded and the cell surface was rinsed with cell maintenance solution for 3 times. Then, 5 ml of cell maintenance solution was added, and then 200 μl of HCoV-229E virus solution was added. The cells were cultured in a 37°C 5% CO2 incubator for 72 to 96 h. The cell lesions were observed under an inverted microscope every day until 80% of the cells showed obvious lesions (CPE). The cell culture flask was placed in a -80°C low-temperature refrigerator for freezing. The virus solution was repeatedly frozen and thawed 3 times before being used for virus titer determination.

[0040] 2.3 Virus titer determination

[0041] Take a 96-well plate with RAW264.7 cells grown into a monolayer, discard the culture medium, rinse the cells 3 times with cell maintenance medium, and inoculate HCoV-229E virus liquid with different titers at a 10-fold ratio (10-1~10-8), with a total of 8 dilutions, 100μl / well, 4 replicates for each dilution, and set up a normal cell control. The 96-well plate was placed in a 37℃ 5% CO2 incubator for 72~96h, and the cell lesions were observed under an inverted microscope every day, and the cell lesions of each well were recorded. The 50% cytopathic concentration (TCID50) was calculated according to the Reed-Muench method.

[0042] 2.4 Construction and drug administration of human coronavirus pneumonia mouse model

[0043] 40 ICR mice were randomly divided into normal control group, model control group, phloroglucinol group, amylmetacresol group, and cresol group according to body weight. There were 8 mice in each group, half of which were male and half were female. Except for the normal control group, mice in other groups were lightly anesthetized with ether and then infected with 100TCID50 HCoV-229E nasal drops, 50μl / mouse. On the day of infection, each dosing group inhaled nebulization for 10 minutes each time, once a day, for 4 consecutive days. After weighing the body weight one day after the last dose, the lungs were dissected and weighed, and the lung index and lung index inhibition rate were calculated.

[0044] 2.5 Calculation of mouse lung index and inhibition rate

[0045] After weighing the mice, the lung tissue was dissected and weighed, and the lung weight was calculated. The lung index and inhibition rate of the mice were calculated. The specific calculation formula is as follows:

[0046] Lung index = lung wet weight (g) × 100 / body weight (g)

[0047]

[0048] 2.6 Statistical analysis

[0049] The data were expressed as (MEAN±SD), and the differences among the groups were tested using T test. P<0.05 was considered statistically significant.

[0050] 3. Experimental Results

[0051] Table 3 Effects of the tested drugs on the mouse model of human coronavirus pneumonia (lung index and inhibition rate)

[0052]

[0053] From the results in Table 3, we can see that compared with the normal control group, the lung index of mice in the model control group was significantly increased (P<0.01); compared with the model control group, the lung index of mice in the cresol group was significantly decreased (P<0.01). Compared with the phloroglucinol group and amylmetacresol group, the cresol group had a good therapeutic effect.

[0054] Test Example 2

[0055] The pneumonia model of mice infected with human coronavirus HCoV-229E was used to evaluate the therapeutic effect of cresol on the pneumonia model of mice infected with human coronavirus HCoV-229E from two aspects: lung index and inhibition rate.

[0056] 1. Experimental Materials

[0057] 1.1 The cell line was mouse mononuclear macrophage RAW264.7, purchased from Beijing Beina Chuanglian Biotechnology Research Institute, passaged in our laboratory, and stored in liquid nitrogen for future use.

[0058] 1.2 The virus strain is human coronavirus HCoV-229E, provided by the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, propagated in this laboratory, and stored in a -80°C refrigerator for future use.

[0059] 1.3 Test drugs: Cresol concentrations were 0.015%, 0.03%, 0.07%, 0.15%, 0.3%, 0.6%, and 1.2%, and the molecular weight was 108.14.

[0060] 1.4 Experimental reagents are shown in Table 4.

[0061] Table 4:

[0062] Reagent name batch number Manufacturer Reagent use Ether 20150417 Sinopharm Chemical Reagent Co., Ltd. Mouse anesthesia

[0063] 1.5 Experimental instruments are shown in Table 5.

[0064] Table 5:

[0065]

[0066] 2. Experimental Methods

[0067] 2.1 Drug preparation

[0068] Preparation of the test drugs: According to Examples 4-10, cresol A group (0.015%), cresol B group (0.03%), cresol C group (0.07%), cresol D group (0.15%), cresol E group (0.3%), cresol F group (0.6%) and cresol G group (1.2%) were prepared and atomized and inhaled at the above concentrations, 10 minutes each time, once a day, for 4 consecutive days.

[0069] 2.2 Virus passaging

[0070] Take a 25cm tube of RAW264.7 cells grown into a monolayer 2 The culture flask was discarded and the cell surface was rinsed with cell maintenance solution for 3 times. Then, 5 ml of cell maintenance solution was added, and then 200 μl of HCoV-229E virus solution was added. The cells were cultured in a 37°C 5% CO2 incubator for 72 to 96 h. The cell lesions were observed under an inverted microscope every day until 80% of the cells showed obvious lesions (CPE). The cell culture flask was placed in a -80°C low-temperature refrigerator for freezing. The virus solution was repeatedly frozen and thawed 3 times before being used for virus titer determination.

[0071] 2.3 Virus titer determination

[0072] Take a 96-well plate with RAW264.7 cells grown into a monolayer, discard the culture medium, rinse the cells 3 times with cell maintenance medium, and inoculate HCoV-229E virus liquid with different titers at a 10-fold ratio (10-1~10-8), with a total of 8 dilutions, 100μl / well, 4 replicates for each dilution, and set up a normal cell control. The 96-well plate was placed in a 37℃ 5% CO2 incubator for 72~96h, and the cell lesions were observed under an inverted microscope every day, and the cell lesions of each well were recorded. The 50% cytopathic concentration (TCID50) was calculated according to the Reed-Muench method.

[0073] 2.4 Construction and drug administration of human coronavirus pneumonia mouse model

[0074] 72 ICR mice were randomly divided into normal control group, model control group and cresol AG group according to body weight. There were 8 mice in each group, half of which were male and half were female. Except for the normal control group, mice in other groups were lightly anesthetized with ether and then infected with 100TCID50 HCoV-229E nasal drops, 50μl / mouse. On the day of infection, each dosing group inhaled nebulization for 10 minutes each time, once a day, for 4 consecutive days. After weighing the body weight one day after the last dose, the lungs were dissected and weighed, and the lung index and lung index inhibition rate were calculated.

[0075] 2.5 Calculation of mouse lung index and inhibition rate

[0076] After weighing the mice, the lung tissue was dissected and weighed, and the lung weight was calculated. The lung index and inhibition rate of the mice were calculated. The specific calculation formula is as follows:

[0077] Lung index = lung wet weight (g) × 100 / body weight (g)

[0078]

[0079] 2.6 Statistical analysis

[0080] The data were expressed as (MEAN±SD), and the differences among the groups were tested using T test. P<0.05 was considered statistically significant.

[0081] 3. Experimental Results

[0082] Table 6 Effects of the test drugs on the mouse model of human coronavirus pneumonia (lung index and inhibition rate)

[0083]

[0084]

[0085] Note: Compared with the normal control group##P<0.01; compared with the model control group*P<0.05, **P<0.01.

[0086] As shown in Table 6, compared with the normal control group, the lung index of mice in the model control group increased significantly (P<0.01); compared with the model control group, the lung index of mice in the five dose groups of cresol B, C, D, E, and F decreased significantly (P<0.05, P<0.01), and the inhibition rates of cresol lung index were 76.56%, 93.08%, 95.50%, 88.44%, and 41.12%, respectively. It can be seen from the experimental results that when the concentration of cresol is within the range of 0.03%-0.6%, the administration groups all show a good effect of inhibiting pneumonia in mice caused by human coronavirus 229E. Among them, group C (0.07%), group D (0.15%) and group E (0.3%) are compared with the model control group P<0.01, which shows that the cresol concentration has a more significant inhibitory effect on pneumonia in mice caused by human coronavirus 229E when it is 0.07%-0.3%. When the concentration of cresol is too low or too high, it does not have a good inhibitory effect.

[0087] Example 1 Phloroglucinol aerosol inhalation preparation

[0088] Phloroglucinol 2g

[0089] Sodium chloride 9.0g

[0090] Add water for injection to 1000ml

[0091] Preparation process:

[0092] Step 1: Weigh 2 g of phloroglucinol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0093] Step 2: Fill into brown ampoule bottle and sterilize by high pressure steam at 115℃ for 30min.

[0094] Example 2 Amylmetacresol aerosol inhalation preparation

[0095] Amylmetacresol 2g

[0096] Sodium chloride 9.0g

[0097] Add water for injection to 1000ml

[0098] Preparation process:

[0099] Step 1: Weigh 2 g of amyl meta-cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0100] Step 2: Fill into brown ampoule bottle and sterilize by high pressure steam at 115℃ for 30min.

[0101] Example 3 Cresol aerosol inhalation preparation

[0102] Cresol 0.7g

[0103] Sodium chloride 9.0g

[0104] Add water for injection to 1000ml

[0105] Preparation process:

[0106] Step 1: Weigh 2 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0107] Step 2: Fill into brown ampoule bottle and sterilize by high pressure steam at 115℃ for 30min.

[0108] Example 4 Cresol aerosol inhalation preparation

[0109] Cresol 0.15g

[0110] Sodium chloride 9.0g

[0111] Add water for injection to 1000ml

[0112] Preparation process:

[0113] Step 1: Weigh 0.18 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0114] Step 2: Fill into brown ampoule bottle under sterile environment and sterilize by high pressure steam at 115℃ for 30min.

[0115] Example 5 Cresol aerosol inhalation preparation

[0116] Cresol 0.3g

[0117] Sodium chloride 9.0g

[0118] Add water for injection to 1000ml

[0119] Preparation process:

[0120] Step 1: Weigh 0.3 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0121] Step 2: Fill into brown ampoule bottle under sterile environment and sterilize by high pressure steam at 115℃ for 30min.

[0122] Example 6 Cresol aerosol inhalation preparation

[0123] Cresol 0.7g

[0124] Sodium chloride 9.0g

[0125] Add water for injection to 1000ml

[0126] Preparation process:

[0127] Step 1: Weigh 0.7 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0128] Step 2: Fill into brown ampoule bottle under sterile environment and sterilize by high pressure steam at 115℃ for 30min.

[0129] Example 7 Cresol aerosol inhalation preparation

[0130] Cresol 1.5g

[0131] Sodium chloride 9.0g

[0132] Add water for injection to 1000ml

[0133] Preparation process:

[0134] Step 1: Weigh 1.5 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0135] Step 2: Fill into brown ampoule bottle under sterile environment and sterilize by high pressure steam at 115℃ for 30min.

[0136] Example 8 Cresol aerosol inhalation preparation

[0137] Cresol 3.0g

[0138] Sodium chloride 9.0g

[0139] Add water for injection to 1000ml

[0140] Preparation process:

[0141] Step 1: Weigh 3.0 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0142] Step 2: Fill into brown ampoule bottle under sterile environment and sterilize by high pressure steam at 115℃ for 30min.

[0143] Example 9 Cresol aerosol inhalation preparation

[0144] Cresol 6.0g

[0145] Sodium chloride 9.0g

[0146] Add water for injection to 1000ml

[0147] Preparation process:

[0148] Step 1: Weigh 6.0 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0149] Step 2: Fill into brown ampoule bottle under sterile environment and sterilize by high pressure steam at 115℃ for 30min.

[0150] Example 10 Cresol aerosol inhalation preparation

[0151] Cresol 12.0g

[0152] Sodium chloride 9.0g

[0153] Add water for injection to 1000ml

[0154] Preparation process:

[0155] Step 1: Weigh 12.0 g of cresol and 9.0 g of sodium chloride, add 1000 ml of water for injection at 20°C to 35°C, dilute, stir evenly, and filter through a 0.22 μm microporous filter membrane;

[0156] Step 2: Fill into brown ampoule bottle under sterile environment and sterilize by high pressure steam at 115℃ for 30min.

Claims

1. Use of cresol in the preparation of drugs for preventing or treating coronavirus infectious diseases; wherein, The cresol has a molecular formula of C7H8O and a molecular weight of 108.14, and is a mixture of o-cresol, m-cresol and p-cresol; The coronavirus infectious disease is pneumonia caused by infection with human coronavirus HCoV-229E; The drug for preventing or treating coronavirus infectious diseases refers to a pharmaceutical preparation containing cresol; the pharmaceutical preparation can be an inhalation preparation; in the inhalation preparation, the mass percentage of cresol is 0.03%-0.6%.

2. The use according to claim 1, characterized in that: In the inhalation preparation, the mass percentage of cresol is 0.07%-0.3%.

3. The use according to claim 2, characterized in that: The inhalation preparation refers to an atomized inhalation solution, the prescription composition of which is cresol, sodium chloride and water for injection; wherein the amount of cresol used is 0.3g-6g, the amount of sodium chloride used is 8.0g-10.0g, and the amount of water for injection is added to a solution volume of 1000ml.

4. The use according to claim 3, characterized in that: The specific preparation method is: Weigh the prescribed amount of cresol and sodium chloride, add 1000 ml of water for injection at 20°C ~ 35°C, dilute and stir evenly, filter through a microporous filter membrane, and prepare according to the aseptic production process to obtain the product.

Citation Information

Patent Citations

  • Anti-SARS vaccine

    CN1572875A

  • Disinfectant cresol and xylenol compsns. - contg. sodium hydroxide and saponified fats, for use in agriculture and stock rearing

    FR2316871A1

  • Pharmaceutical compositions containing a cresol or a mixture of cresols

    GB997975A

  • Medicinal composition having antiviral-Anti-inflammatory activity

    JP2006306836A

  • Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol

    WO2005067906A2